USPatent applicationPatented

Oral supplement composition containing a plurality of mushroom strains

Granted 19 Oct 2004 · 1 office action

Current assignee: EAST WEST BANK · originally Gaisford and Miller, Inc.

Law firm: Law firm · Log in to unlock

Attorney: Attorney · Log in to unlock

Inventors: Andrew H. Miller, Kelly N. Gaisford, Alec D. Keith · Examiner: Christopher R. Tate · AU 1654 · TC 1600

Life of the application

14 dated events
⤢ drag to zoom20022004200620082010201220142016201820202022ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

An oral supplement composition and method of making and using it, in which a combination of fourteen different specialized mushroom species, each of which has its own unique immunomodulatory properties, demonstrate enhancement of the immune system. When taken together, the combination of mushroom species exert a potentiated, synergistic effect that enhances immune function greater than the sum of each mushroom species\' immunoenhancing influence. The oral supplement can be prepared into a variety of dosage forms, such as capsules, caplets, tablets, pills, dispersions, suspensions, solution, powders, teas, or syrup concentrates, and can be packaged in bottles or other packaging for sale.

Description

9 parts
›CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application No. 60/324,163, filed Sep. 21, 2001, which is incorporated herein by reference.

›BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to an oral supplement composition and to a process for the production of the same. More particularly, fourteen different species of mushrooms are disclosed that exert enhanced immune function when taken together as a daily supplement.

2. Description of Related Art

The immune system is the body's basic protection and serves as both its essential mechanism for healing and its defense against premature aging. In general, it is believed that foodstuffs such as mushrooms, garlic, ginseng, American aloe and the like are effective in the promotion of human health, typically by enhancing immune function. It is well known there are many vitamins and minerals, essential fatty acids, proteins and carbohydrates which are required to sustain immune function. Recently the inadequate consumption of vitamins, minerals and essential-unsaturated fatty acids has been linked to various diseases, particularly those diseases of aging such as arthritis and cancer as well as others. A number of naturally-occurring ingredients in substances not normally included in the diet are known to inhibit or to reduce the growth of tumor cells, which suggests their immune-enhancing effect. Some examples of these items include herbs, edible fungus, e.g. mushrooms and antioxidants from natural raw sources such as grape seed or the Merritime pine bark.

Indeed, various mushroom species have been employed for centuries in Asian medicine, and their role in supporting immune function is currently being investigated in the scientific community. All plants produce certain kinds of sugars that are a source of energy and that form the cell walls in some plants. Some of the complex sugars in mushrooms are called alpha and beta glucans and are the focus of studies concerning their effects on the human immune system. Beta glucans are not produced naturally in humans, and must therefore come from plant and animal sources. Maitake mushrooms, for example, are exceptionally high in beta glucans, while shiitake mushrooms have high concentrations of alpha glucans.

Oral nutraceuticals have become very popular in recent years as research uncovers those specific compounds contained in food that have immunomodulatory effects. Thus, there is a continuing need for an oral supplement that exerts enhancement of the immune system in new and unexpected ways.

›SUMMARY OF THE INVENTION

Accordingly, it is the object of the present invention to provide an oral supplement that contains a novel composition of mushroom species, which species have been shown to enhance immune function via bio-directed immunity. The oral supplement composition of the invention comprises a unique blend of fourteen different mushroom (fungi) species, each having its own properties that have been shown to have beneficial effects on the immune system. Moreover, when taken together, the combination of mushroom species exerts a potentiated, synergistic effect that boosts immune function to an extent greater than the sum of each mushroom species' immunomodulatory effect.

The oral supplement can be prepared into a variety of dosage forms, such as capsules, caplets, tablets, pills, dispersions, suspensions, solution, powders, teas, or syrup concentrates, and can be packaged in bottles or other packaging for sale. The advantages of such an oral composition will be more fully apparent in view of the following detailed description.

›DESCRIPTION OF THE PREFERRED EMBODIMENT

The novel composition of the present invention is a nutraceutical created as an oral supplement composition containing a specialized blend of fourteen different mushroom (fungi) species that support and enhance the body's natural defenses via bio-directed immunity. The oral supplement provides a unique combination of natural organic compounds, based on extensive research in mushroom science, that includes rare varieties and specialized mushroom species, each having it own properties, some of which are found naturally only in hard-to-access regions, such as tropical rainforests and other remote areas of the world. For instance, Ganoderma lucidum has been traditionally known and used in oriental medicine for its antitumor effects but is unfamiliar and difficult to find in the United States.

The different specialized mushroom species of the present invention are grown in Hawaii under laboratory conditions for consistent results. Following is a list of the fourteen species of mushrooms and their active ingredient weight percentages: Cordyceps sinensis: 6% to 14%, more preferably 8% to 12%, most preferably 10%; Agaricus blazei : 4% to 12%, more preferably 6% to 10%, most preferably 8%; Grifola frondosus: 4% to 12%, more preferably 6% to 10%, most preferably 8%; Ganoderma lucidum: 4% to 12%, more preferably 6% to 10%, most preferably 8%; Trametes versicolor: 4% to 12%, more preferably 6% to 10%, most preferably 8%; Lentinula edodes: 4% to 12%, more preferably 6% to 10%, most preferably 8%; Hericium erinaceus : 4% to 12%, more preferably 6% to 10%, most preferably 8%; Tremella mesenterica : 2% to 10%, more preferably 4% to 8%, most preferably 6%; Phellinus linteus : 2% to 10%, more preferably 4% to 8%, most preferably 6%; Pleurotus tuber - regium : 2% to 10%, more preferably 4% to 8%, most preferably 6%; Pleurotus ostreatus: 2% to 10%, more preferably 4% to 8%, most preferably 6%; Inonotus obliquus : 2% to 10%, more preferably 4% to 8%, most preferably 6%; Lepiota procera : 2% to 10%, more preferably 4% to 8%, most preferably 6%; and Flammulina velutipes: 2% to 10%, more preferably 4% to 8%, most preferably 6%.

The fourteen mushroom species are grown under axenic (meaning only one life form) conditions in the vegetative state and on a sterile substrate of organic whole grain. The optimal growing temperature is between 60° C. and 70° C. After harvesting, each mushroom species is individually dried (to a moisture content less than 5%). The dried mushroom is then formed into a powder and mixed with the other similarly prepared thirteen mushroom species to form an admixture. The admixture is ground to between 60 and 80 mesh and autoclave sterilized. After sterilization, the admixture can be prepared into dosage forms that include, without limitation, capsules, caplets, tablets, pills, dispersions, suspensions, solution, powders, teas, or syrup concentrates. The final product can then be packaged in bottles or other packaging for sale. When the final product is provided in capsule form, it also typically contains up to five parts by weight of the inactive ingredient magnesium stearate encapsulated in a vegetarian cellulose derivative, such as hydroxypropyl methylcellulose. When the final product is packaged as tablet, it also typically contains inactive ingredients, such as up to 2.5 parts by weight of acacia-based gum and up to 2.5 parts by weight of silicon dioxide. Alternative standard pharmaceutical ingredients may be substituted for the cellulose derivates, magnesium stearate, acacia-based gum and silicon dioxide according to the ordinary skill in the pharmaceutical arts.

Mushrooms are in the fungi phylum and have complex life cycles containing both a vegetative and a sexual cycle. During the sexual cycle the typical mushroom-shaped structure is produced containing spores. The spores germinate and grow producing 1 N hyphae. Later, opposite mating types of germ hyphae will fuse and produce a 2 N structure that is then in the vegetative growth phase. The vegetative growth continues until some great stress occurs interfering with their growth. This stressful condition induces the fungus (mushroom) to enter the sexual phase.

It has become apparent that different mushroom species vary substantially in their respective chemical fingerprints, and each species chosen for bio-directed immunity has unique chemical and immunomodulatory properties. Each of the mushroom species has a unique polysaccharide fraction that has been shown to have beneficial effects on the immune system. The purpose of preparing a cocktail of fourteen different specialized mushroom species is to maximize the chemical diversity of the mixture. Because different naturally occurring chemicals promote immunity in different ways, the fourteen mushroom species composition is better than any one or any lesser number of species. Indeed, it is the unique combinations of the enumerated components which give this oral supplement its potency for enhancing immune function. Thus, when taken together, the fourteen organically-grown, scientifically optimized specialized mushroom species exert a potentiated, synergistic effect that enhances immune function greater than the sum of each mushroom species' immunomodulatory influence.

›Examples5
›EXAMPLE 1

The following composition of mushroom species was used to prepare a 500 mg oral supplement packaged in capsule form. Inactive ingredients consisted of magnesium stearate and hydroxypropyl methylcellulose. The recommended daily dose of two capsules were taken separately during the day for maximum absorption.

Ingredient

Amount (% total weight active ingredients)

Cordyceps sinensis

10

Agaricus blazei

8

Grifola frondosus

8

Ganoderma lucidum

8

Trametes versicolor

8

Lentinula edodes

8

Hericium erinaceus

8

Tremella mesenterica

6

Phellinus linteus

6

Pleurotus tuber-regium

6

Pleurotus ostreatus

6

Inonotus obliquus

6

Lepiota procera

6

Flammulina velutipes

6

›EXAMPLE 2

The following composition of mushroom species can be prepared as a 500 mg oral supplement packaged in tablet form. Inactive ingredients are acacia-based gum and silicon dioxide. A recommended daily dose of two tablets should be taken separately during the day for maximum absorption.

Ingredient

Amount (% total weight active ingredients)

Cordyceps sinensis

14

Agaricus blazei

4

Grifola frondosus

12

Ganoderma lucidum

4

Trametes versicolor

12

Lentinula edodes

4

Hericium erinaceus

12

Tremella mesenterica

2

Phellinus linteus

10

Pleurotus tuber-regium

2

Pleurotus ostreatus

10

Inonotus obliquus

2

Lepiota procera

10

Flammulina velutipes

2

›EXAMPLE 3

The following composition of mushroom species can be prepared as a 500 mg oral supplement packaged in tablet form. Inactive ingredients are acacia-based gum and silicon dioxide. A recommended daily dose of two tablets should be taken separately during the day for maximum absorption.

Ingredient

Amount (% total weight active ingredients)

Cordyceps sinensis

6

Agaricus blazei

12

Grifola frondosus

4

Ganoderma lucidum

12

Trametes versicolor

4

Lentinula edodes

12

Hericium erinaceus

4

Tremella mesenterica

10

Phellinus linteus

2

Pleurotus tuber-regium

10

Pleurotus ostreatus

2

Inonotus obliquus

10

Lepiota procera

2

Flammulina velutipes

10

›EXAMPLE 4

The following composition of mushroom species can be prepared as a 500 mg oral supplement packaged in caplet form. Inactive ingredients are acacia-based gum and silicon dioxide. A recommended daily dose of two tablets should be taken separately during the day for maximum absorption.

Ingredient

Amount (% total weight active ingredients)

Cordyceps sinensis

12

Agaricus blazei

6

Grifola frondosus

10

Ganoderma lucidum

6

Trametes versicolor

10

Lentinula edodes

6

Hericium erinaceus

10

Tremella mesenterica

4

Phellinus linteus

8

Pleurotus tuber-regium

4

Pleurotus ostreatus

8

Inonotus obliquus

4

Lepiota procera

8

Flammulina velutipes

4

›EXAMPLE 5

The following composition of mushroom species can be prepared as a 500 mg oral supplement packaged in caplet form. Inactive ingredients are acacia-based gum and silicon dioxide. A recommended daily dose of two tablets should be taken separately during the day for maximum absorption.

Ingredient

Amount (% total weight active ingredients)

Cordyceps sinensis

8

Agaricus blazei

10

Grifola frondosus

6

Ganoderma lucidum

10

Trametes versicolor

6

Lentinula edodes

10

Hericium erinaceus

6

Tremella mesenterica

8

Phellinus linteus

4

Pleurotus tuber-regium

8

Pleurotus ostreatus

4

Inonotus obliquus

8

Lepiota procera

4

Flammulina velutipes

8

The present invention has been described with reference to specific details of particular embodiments thereof. It is not intended that such details be regarded as limitations upon the scope of the invention except insofar as and to the extent that they are included in the accompanying claims.

Claims as granted

27 claims

Log in to read the claims of this application.

Log in to unlock

Classifications

3 codes
IPC · International Patent Classification
Section A — Human necessities
  • A61K3/584
USPC · US Patent Classification
424/195.15514/885

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoomOct 2002Jan 2003Apr 2003Jul 2003Oct 2003Jan 2004Apr 2004Jul 2004Oct 2004USPTOApplicantNon-final rejectionResponse after non-finalNotice of allowance
USPTOApplicanthover for detail · click to open
Pendency
2.1 y
757 days filing → grant
Office actions
1
non-final + final
Responses
1
no RCE
Examiner
Christopher R. Tate
art unit 1654 · TC 1600
Citations: 11 back · 2 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

⤢ drag to zoom2004200620082010201220142016201820202022Owner 1Owner 2Owner 4liens, releases & corrections
TitleLienhover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock